gefitinib has been researched along with rabeprazole in 3 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (rabeprazole) | Trials (rabeprazole) | Recent Studies (post-2010) (rabeprazole) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 1,073 | 446 | 405 |
| Protein | Taxonomy | gefitinib (IC50) | rabeprazole (IC50) |
|---|---|---|---|
| Adenosine receptor A3 | Homo sapiens (human) | 3.219 | |
| Urease subunit alpha | Helicobacter pylori 26695 | 0.29 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.219 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 1.737 | |
| D(3) dopamine receptor | Homo sapiens (human) | 2.326 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.219 | |
| WD repeat-containing protein 5 | Homo sapiens (human) | 0.49 | |
| Urease subunit beta | Helicobacter pylori 26695 | 0.29 | |
| Histone-lysine N-methyltransferase 2A | Homo sapiens (human) | 0.49 | |
| NAD(+) hydrolase SARM1 | Homo sapiens (human) | 3.25 | |
| Cytosolic endo-beta-N-acetylglucosaminidase | Homo sapiens (human) | 4.47 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 8.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
2 review(s) available for gefitinib and rabeprazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 other study(ies) available for gefitinib and rabeprazole
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |